Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
| ▸ | CYP1A1 | P04798 | 3/20 | 0.35 |
| ▸ | CYP1B1 | Q16678 | 3/20 | 0.35 |
| ▸ | PTGS2 | P35354 | 4/20 | 0.33 |
| ▸ | CYP1A2 | P05177 | 3/20 | 0.32 |
| ▸ | CYP2E1 | P05181 | 2/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.32 |
| ▸ | CYP2C8 | P10632 | 2/20 | 0.32 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.32 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.32 |
| ▸ | CYP4B1 | P13584 | 2/20 | 0.32 |
| ▸ | CYP2B6 | P20813 | 2/20 | 0.32 |
| ▸ | CYP3A5 | P20815 | 2/20 | 0.32 |
| ▸ | CYP2A7 | P20853 | 2/20 | 0.32 |
| ▸ | CYP3A7 | P24462 | 2/20 | 0.32 |
| ▸ | CYP2F1 | P24903 | 2/20 | 0.32 |
| ▸ | CYP2C18 | P33260 | 2/20 | 0.32 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7399351 | 0.88 | ESR1 (0.40) | ALDH1A1KMT2APTGS2AKR1C3AKR1C2 | |
| SCHEMBL7749051 | 0.82 | AOC3 (0.45) | — | |
| SCHEMBL8716433 | 0.80 | RAB9A (0.46) | ALDH1A1KMT2APTGS2CYP1A2CYP2D6 | |
| SCHEMBL4617166 | 0.73 | CYP2D6 (0.37) | ALDH1A1KMT2ACYP1A2CYP3A4CYP2D6 | |
| SCHEMBL28212652 | 0.72 | ALDH1A1 (0.44) | ALDH1A1KMT2ACYP1A1CYP1B1PTGS2 | |
| SCHEMBL5497954 | 0.72 | ALDH1A1 (0.39) | ALDH1A1KMT2ACYP1A1CYP1B1 | |
| SCHEMBL2125711 | 0.72 | TAAR1 (0.42) | ALDH1A1KMT2ATSHRMEN1 | |
| SCHEMBL5897956 | 0.72 | ALDH1A1 (0.55) | ALDH1A1KMT2ACYP1A1CYP1B1PTGS2 | |
| SCHEMBL40553 | 0.71 | ALDH1A1 (0.61) | ALDH1A1KMT2ACYP1A1CYP1B1PTGS2 | |
| SCHEMBL27643039 | 0.71 | KMT2A (0.44) | ALDH1A1KMT2APTGS2CYP1A2PTGS1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 49 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD (IE) | 2015-02-26 | — | — | US | disclosed |
| US-8937048-B2 | Anti-angiogenic compounds | COVX TECHNOLOGIES IRELAND, LIMITED (IE) | 2015-01-20 | — | — | US | disclosed |
| US-8912148-B2 | Methods of treating a disease or condition associated with abnormal angiogenesis | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2014-12-16 | — | — | US | disclosed |
| EP-1997533-B1 | Heterocyclic boronic acid compounds, dipeptidyl peptidase IV inhibitors | PHENOMIX CORP (US) | 2014-09-24 | — | — | EP | disclosed |
| EP-1689757-B1 | HETEROCYCLIC BORONIC ACID COMPOUNDS | PHENOMIX CORP (US) | 2014-08-27 | — | — | EP | disclosed |
| US-8415295-B2 | Heterocyclic boronic acid compounds | PHENOMIX CORPORATION (US) | 2013-04-09 | — | — | US | disclosed |
| US-20120321591-A1 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND, LIMITED | 2012-12-20 | — | — | US | disclosed |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | COVX TECHNOLOGIES IRELAND LTD. | 2012-11-29 | — | — | US | disclosed |
| US-8299271-B2 | Solid tartrate salts of DPP-IV inhibitors | PHENOMIX CORPORATION (US) | 2012-10-30 | — | — | US | disclosed |
| US-8293714-B2 | Anti-angiogenic compounds | COVX TECHNOLOGY IRELAND, LTD. (IE) | 2012-10-23 | — | — | US | disclosed |
| WO-2007016356-A1 | METHODS OF PREPARING HETERCYCLIC BORONIC ACIDS AND DERIVATIVES THEREOF | PHENOMIX CORPORATION (US) | 2007-02-08 | — | — | WO | disclosed |
| EP-1743676-A1 | Heterocyclic boronic acid derivatives, dipeptidyl peptidase IV inhibitors | Phenomix Corporation (US) | 2007-01-17 | — | — | EP | disclosed |
| US-20060276410-A1 | COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | Forest Laboratories Holding Limited (BM) | 2006-12-07 | — | — | US | disclosed |
| US-20060264401-A1 | METHYL AND ETHYL SUBSTITUTED PYRROLIDINE COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | PHENOMIX CORPORATION | 2006-11-23 | — | — | US | disclosed |
| US-20060264400-A1 | PYRROLIDINE COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | SINO-MED INTERNATIONAL ALLIANCE, INC. | 2006-11-23 | — | — | US | disclosed |
| US-20060258621-A1 | PYRROLIDINE COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | SINO-MED INTERNATIONAL ALLIANCE, INC. | 2006-11-16 | — | — | US | disclosed |
| US-20060205670-A1 | Conjugated to antibody; thrombospondin receptor targeting | ZOETIS BELGIUM S.A. (BE) | 2006-09-14 | — | — | US | disclosed |
| WO-2006094269-A2 | ANTI-ANGIOGENIC COMPOUNDS | COVX TECHNOLOGIES IRELAND LIMITED (IE) | 2006-09-08 | — | — | WO | disclosed |
| WO-2004091542-A2 | NITROGEN CONTAINING INTEGRIN TARGETING COMPOUNDS | COVX PHARMACEUTICALS, INC. (US) | 2004-10-28 | — | — | WO | disclosed |
| US-6124341-A | A DRUG FOR TREATING HYPERTENSION, CONGESTIVE HEART FAILURE, RESTENOSIS FOLLOWING ARTERIAL INJURY, CEREBRAL OR MYOCARDIAL ISCHEMIA OR ATHEROSCLEROSIS; VASODILUTOR | ABBOTT LABORATORIES (US) | 2000-09-26 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060276410-A1 | COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | DPP4, DPP3, DPP7 | ALDH1A1 792/4885KMT2A 4535/4885CYP1A1 2009/4885 |
| US-20060205670-A1 | Conjugated to antibody; thrombospondin receptor targeting | TEK, KDR, FLT4 | ALDH1A1 1830/4885KMT2A 3959/4885CYP1A1 4815/4885 |
| US-20120301431-A1 | METHODS OF TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, FLT4, TEK | ALDH1A1 807/4885KMT2A 2356/4885CYP1A1 4792/4885 |
| US-20150057431-A1 | COMPOSITIONS FOR TREATING A DISEASE OR CONDITION ASSOCIATED WITH ABNORMAL ANGIOGENESIS | VEGFA, TIE1, TEK | ALDH1A1 1018/4885KMT2A 2729/4885CYP1A1 4770/4885 |
| US-20060264400-A1 | PYRROLIDINE COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | DPP4, DPP7, DPP3 | ALDH1A1 983/4885KMT2A 2682/4885CYP1A1 3854/4885 |
| US-20120321591-A1 | ANTI-ANGIOGENIC COMPOUNDS | VEGFA, FLT4, FLT1 | ALDH1A1 2557/4885KMT2A 4308/4885CYP1A1 4877/4885 |
| US-20060258621-A1 | PYRROLIDINE COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | DPP4, DPP7, DPP3 | ALDH1A1 1030/4885KMT2A 2805/4885CYP1A1 3881/4885 |
| US-20060264401-A1 | METHYL AND ETHYL SUBSTITUTED PYRROLIDINE COMPOUNDS AND METHODS FOR SELECTIVE INHIBITION OF DIPEPTIDYL PEPTIDASE-IV | DPP4, DPP3, DPP7 | ALDH1A1 1520/4885KMT2A 1313/4885CYP1A1 3692/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.